- Valuation
- ₹9,840 Cr

About Akums Drugs and Pharmaceuticals Limited
Data last updated:
Akums Drugs and Pharmaceuticals Limited is a public limited company based in Delhi, India. It operates in the chemical products segment of the chemicals sector. It was incorporated on 19 April 2004 and has been in existence for over 22 years.
Its director Sanjeev Jain is #655 among India's richest people (2026). Its director Sandeep Jain is #655 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN L24239DL2004PLC125888. Its GSTIN is 07AAECA7090B2ZX (Delhi). The company holds 9 GST registrations, of which 5 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 544222 and NSE: AKUMS.
The company has an authorised share capital of ₹40 Cr and a paid-up capital of ₹31.48 Cr. It is led by directors including Sandeep Jain (Managing Director) and Sanjeev Jain (Managing Director).
Its last annual general meeting (AGM) was held on 10 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 304 Mohan Placelsc Saraswati Vihar, Delhi, India – 110034.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹4,359.02 Cr, a growth of 5.8% compared to the previous year. For the same year it recorded a net profit of ₹268.66 Cr (net margin 6.2%) and EBITDA of ₹502.01 Cr (EBITDA margin 11.5%). The net worth stands at ₹3,313.35 Cr (up 8.7% YoY). Total assets are valued at ₹4,415.09 Cr (up 37% YoY).
The company has about 1,707 employees on its provident fund (EPFO) records. Its group structure includes 14 subsidiaries.
The company is associated with 3 brands: Unosource Pharma, Akums and Akumentis Heathcare. As per MCA filings, the company has open charges of ₹85 Cr and satisfied charges of ₹468.39 Cr on record. Court records list 206 cases involving the company, including 138 filed by the company and 68 filed against it; 51 cases are pending. The company has 13 deals on record (9 secondary share transfers, 2 market trades, 1 ipo), with disclosed funding of ₹320 Cr; the latest was in December 2025. Its 5 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations) are compared by revenue, 2 larger and 3 smaller; the largest is Strides Pharma Science Limited with revenue of ₹4,624.06 Cr. The company has 2 MSME Form 1 returns on record between 2019 and 2021, listing 8 overdue payments to 8 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website akums.in.
Company details
CIN history
Akums Drugs and Pharmaceuticals has one previous CIN (Corporate Identification Number): U24239DL2004PLC125888. The current CIN is L24239DL2004PLC125888, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24239DL2004PLC125888 | Current |
| U24239DL2004PLC125888 | Previous |
Recognitions & Rankings of Akums Drugs and Pharmaceuticals
- #655 Sanjeev Jain ₹4,900 Cr
- #655 Sandeep Jain ₹4,900 Cr
Contact details
Akums Drugs and Pharmaceuticals Limited's registered office is in Delhi, Delhi. Its website is akums.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address304 Mohan Placelsc Saraswati Vihar, Delhi, India – 110034
- IndustryChemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals
To see the full contact details of Akums Drugs and Pharmaceuticals Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Akums Drugs and Pharmaceuticals operates multiple associated brands including Unosource Pharma, Akums, and Akumentis Heathcare. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical manufacturing, exporting, and CDMO services. | unosourcepharma.com | |
| CDMO focusing on spectrum of dosage forms and therapeutic segments | akums.in | |
| Pharmaceutical products are manufactured across multiple therapeutic areas. | akumentishealthcare.com |
Business activity
The main business activity of Akums Drugs and Pharmaceuticals is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations |
To see the full business activity and turnover split of Akums Drugs and Pharmaceuticals Limited, buy the company report.
Financials of Akums Drugs and Pharmaceuticals Limited
FY 2025-26 filings availableAkums Drugs and Pharmaceuticals Limited reported revenue of ₹4,359.02 Cr (up 5.8% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 4,359 | 4,118 | 4,178 | 3,655 | 3,672 | 2,723 | 2,414 |
| Revenue growth | +5.9% | -1.4% | +14.3% | -0.5% | +34.9% | +12.8% | - |
| EBITDA | 502 | 464 | 96.95 | 219 | (105) | 227 | 173 |
| EBITDA margin | +11.5% | +11.3% | +2.3% | +6.0% | -2.9% | +8.4% | +7.2% |
| Profit before tax | 382 | 345 | (45.27) | 150 | (193) | 172 | 114 |
| Net profit | 269 | 323 | (20.67) | 127 | (244) | 130 | 44.09 |
| Net profit margin | +6.2% | +7.8% | -0.5% | +3.5% | -6.6% | +4.8% | +1.8% |
| EPS (₹) | 16.67 | 22.09 | (0.28) | 6.63 | (35.30) | 943.16 | 335.65 |
| Balance sheet | |||||||
| Total assets | 4,415 | 3,222 | 2,713 | 2,404 | 2,109 | 1,647 | 1,439 |
| Net worth | 3,313 | 3,047 | 710 | 717 | 622 | 885 | 722 |
| Total debt | 157 | 88.22 | 565 | 619 | 395 | 130 | 175 |
| Cash & bank | 1,681 | 576 | 277 | 150 | 103 | 67.87 | 147 |
| Net working capital | 2,546 | 1,402 | 1,149 | 1,042 | 943 | 659 | 679 |
| Cash flow | |||||||
| Cash from operations | 1,181 | 465 | 498 | 177 | 31.85 | 131 | 28.13 |
| Cash from investing | (930) | (548) | (331) | (305) | (235) | (109) | (190) |
| Cash from financing | 33.88 | 72.79 | (108) | 125 | 236 | (91.46) | 233 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,342 | 1,167 | 1,158 | 1,160 | 1,018 | 1,024 | 1,056 | 1,010 |
| Revenue growth (YoY) | +31.9% | +13.9% | +9.7% | +14.8% | -1.5% | +0.5% | - | - |
| Other income | 28.91 | 30.38 | 35.30 | 34.33 | 32.37 | 26.73 | 25.76 | 19.34 |
| EBITDA | 195 | 175 | 150 | 129 | 94.48 | 129 | 93.92 | 121 |
| EBITDA margin | +14.5% | +15.0% | +12.9% | +11.1% | +9.3% | +12.6% | +8.9% | +12.0% |
| Depreciation | 43.21 | 41.07 | 40.12 | 39.65 | 37.86 | 36.92 | 40.00 | 44.52 |
| Interest | 25.68 | 24.76 | 23.89 | 23.74 | 23.30 | 23.14 | 4.54 | 5.13 |
| Profit before tax | 155 | 139 | 121 | 99.57 | 65.69 | 95.64 | 75.14 | 91.05 |
| Tax | 40.18 | 38.26 | 39.87 | 31.89 | 22.98 | 30.96 | (74.47) | 24.75 |
| Net profit | 115 | 101 | 81.35 | 67.68 | 42.71 | 64.68 | 150 | 66.30 |
| EPS (₹) | 7.37 | 6.53 | 5.53 | 4.33 | 2.66 | 4.15 | 9.64 | 4.26 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,349 | 1,312 | 1,444 | 1,287 | 1,162 | 837 | 737 |
| Revenue growth | +2.8% | -9.2% | +12.2% | +10.7% | +38.8% | +13.6% | - |
| EBITDA | 90.96 | 138 | (146) | 97.34 | (362) | (223) | 39.93 |
| EBITDA margin | +6.7% | +10.6% | -10.1% | +7.6% | -31.2% | -26.6% | +5.4% |
| Profit before tax | 148 | 208 | (103) | 150 | (335) | (195) | 75.85 |
| Net profit | 117 | 158 | (157) | 231 | (383) | 110 | 50.84 |
| Net profit margin | +8.6% | +12.1% | -10.9% | +17.9% | -32.9% | +13.2% | +6.9% |
| EPS (₹) | 7.29 | 10.52 | (11.56) | 8.77 | (53.37) | (1,117.82) | 391.04 |
| Balance sheet | |||||||
| Total assets | 2,516 | 2,374 | 1,796 | 1,521 | 1,389 | 1,176 | 1,262 |
| Net worth | 2,428 | 2,305 | 144 | 312 | 186 | 567 | 712 |
| Total debt | 59.21 | 46.29 | 267 | 146 | 140 | 41.13 | 35.80 |
| Cash & bank | 771 | 356 | 73.31 | 8.85 | 25.74 | 1.00 | 72.48 |
| Net working capital | 1,035 | 530 | 244 | 148 | 143 | 230 | 352 |
| Cash flow | |||||||
| Cash from operations | (2.15) | 91.00 | 248 | 94.01 | 228 | 55.57 | (21.75) |
| Cash from investing | (24.97) | (459) | (165) | (202) | (298) | (99.96) | (242) |
| Cash from financing | (3.00) | 375 | (20.74) | 89.90 | 94.99 | 2.60 | 302 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 395 | 392 | 338 | 369 | 309 | 332 | 329 | 337 |
| Revenue growth (YoY) | +27.7% | +18.0% | +2.9% | +9.3% | -5.8% | +4.8% | - | - |
| Other income | 25.80 | 26.10 | 27.73 | 29.60 | 27.08 | 28.56 | 32.05 | 33.84 |
| Total expenses | 360 | 344 | 329 | 348 | 292 | 288 | 311 | 303 |
| EBITDA | 34.57 | 48.51 | 9.07 | 20.87 | 16.90 | 44.10 | 17.72 | 34.03 |
| EBITDA margin | +8.8% | +12.4% | +2.7% | +5.7% | +5.5% | +13.3% | +5.4% | +10.1% |
| Depreciation | 13.51 | 12.80 | 12.42 | 12.15 | 10.69 | 10.25 | 10.09 | 10.68 |
| Interest | 3.00 | 2.48 | 2.59 | 2.46 | 2.08 | 2.91 | 2.63 | 2.29 |
| Profit before tax | 43.86 | 59.33 | 21.79 | 35.86 | 31.21 | 59.50 | 37.05 | 54.90 |
| Tax | 11.21 | 14.50 | 6.60 | 7.75 | 7.74 | 14.64 | 9.47 | 13.73 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,342 | 1,167 | 1,158 | 1,160 | 1,018 | 1,024 | 1,056 | 1,010 |
| Revenue growth (YoY) | +31.9% | +13.9% | +9.7% | +14.8% | -1.5% | +0.5% | - | - |
| Other income | 28.91 | 30.38 | 35.30 | 34.33 | 32.37 | 26.73 | 25.76 | 19.34 |
| EBITDA | 195 | 175 | 150 | 129 | 94.48 | 129 | 93.92 | 121 |
| EBITDA margin | +14.5% | +15.0% | +12.9% | +11.1% | +9.3% | +12.6% | +8.9% | +12.0% |
| Depreciation | 43.21 | 41.07 | 40.12 | 39.65 | 37.86 | 36.92 | 40.00 | 44.52 |
| Interest | 25.68 | 24.76 | 23.89 | 23.74 | 23.30 | 23.14 | 4.54 | 5.13 |
| Profit before tax | 155 | 139 | 121 | 99.57 | 65.69 | 95.64 | 75.14 | 91.05 |
| Tax | 40.18 | 38.26 | 39.87 | 31.89 | 22.98 | 30.96 | (74.47) | 24.75 |
| Net profit | 115 | 101 | 81.35 | 67.68 | 42.71 | 64.68 | 150 | 66.30 |
| EPS (₹) | 7.37 | 6.53 | 5.53 | 4.33 | 2.66 | 4.15 | 9.64 | 4.26 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 4,359 | 4,118 | 4,178 | 3,655 | 3,672 | 2,723 | 2,414 |
| Revenue growth | +5.9% | -1.4% | +14.3% | -0.5% | +34.9% | +12.8% | - |
| Other income | 129 | 68.82 | 34.03 | 90.07 | 22.83 | 21.50 | 27.49 |
| Total expenses | 3,857 | 3,654 | 4,081 | 3,436 | 3,777 | 2,495 | 2,241 |
| Employee cost | 754 | 716 | 647 | 590 | 508 | 425 | 439 |
| EBITDA | 502 | 464 | 96.95 | 219 | (105) | 227 | 173 |
| EBITDA margin | +11.5% | +11.3% | +2.3% | +6.0% | -2.9% | +8.4% | +7.2% |
| Depreciation | 155 | 153 | 126 | 113 | 94.68 | 69.84 | 66.68 |
| Interest | 94.07 | 34.60 | 50.61 | 46.25 | 16.66 | 6.74 | 19.93 |
| Profit before tax | 382 | 345 | (45.27) | 150 | (193) | 172 | 114 |
| Tax | 126 | 1.48 | (46.07) | 52.48 | 57.68 | 48.83 | 70.17 |
| Net profit | 269 | 323 | (20.67) | 127 | (244) | 130 | 44.09 |
| Net profit margin | +6.2% | +7.8% | -0.5% | +3.5% | -6.6% | +4.8% | +1.8% |
| EPS (₹) | 16.67 | 22.09 | (0.28) | 6.63 | (35.30) | 943.16 | 335.65 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 30.62 | 30.62 | 28.61 | 28.61 | 14.31 | 1.30 | 1.30 |
| Reserves & surplus | 3,283 | 3,016 | 681 | 689 | 608 | 884 | 721 |
| Shareholders' funds (net worth) | 3,313 | 3,047 | 710 | 717 | 622 | 885 | 722 |
| Minority interest | 17.77 | 16.60 | 10.99 | 6.19 | 3.20 | 2.29 | (1.51) |
| Secured loans | 72.95 | 13.66 | 391 | 537 | 358 | 95.90 | 140 |
| Unsecured loans | 84.48 | 74.56 | 174 | 82.12 | 37.03 | 34.07 | 35.02 |
| Total debt | 157 | 88.22 | 565 | 619 | 395 | 130 | 175 |
| Total liabilities | 4,415 | 3,222 | 2,713 | 2,404 | 2,109 | 1,647 | 1,439 |
| Assets | |||||||
| Gross block | 2,410 | 2,242 | 1,882 | 1,683 | 1,518 | 1,321 | 993 |
| Net block | 1,456 | 1,397 | 1,191 | 1,097 | 1,021 | 904 | 645 |
| Capital work in progress | 177 | 163 | 195 | 103 | 31.07 | 17.01 | 56.60 |
| Investments | 0.14 | 0.14 | 0.14 | 0.14 | 0.39 | 19.54 | 5.84 |
| Inventories | 756 | 681 | 630 | 730 | 722 | 430 | 398 |
| Sundry debtors | 797 | 770 | 834 | 845 | 884 | 531 | 582 |
| Cash & bank balances | 1,681 | 576 | 277 | 150 | 103 | 67.87 | 147 |
| Loans & advances | 327 | 247 | 200 | 154 | 154 | 109 | 117 |
| Total current assets | 3,560 | 2,275 | 1,941 | 1,879 | 1,864 | 1,138 | 1,244 |
| Total current liabilities | 1,014 | 873 | 792 | 837 | 921 | 479 | 565 |
| Net working capital | 2,546 | 1,402 | 1,149 | 1,042 | 943 | 659 | 679 |
| Total assets | 4,415 | 3,222 | 2,713 | 2,404 | 2,109 | 1,647 | 1,439 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 101 | 111 | 51.61 | 55.14 | 22.07 | 91.79 | 20.51 |
| Net cash from operating activities | 1,181 | 465 | 498 | 177 | 31.85 | 131 | 28.13 |
| Net cash from investing activities | (930) | (548) | (331) | (305) | (235) | (109) | (190) |
| Net cash from financing activities | 33.88 | 72.79 | (108) | 125 | 236 | (91.46) | 233 |
| Net change in cash | 285 | (9.86) | 59.44 | (3.53) | 33.07 | (69.72) | 71.28 |
| Closing cash | 1,681 | 576 | 277 | 150 | 103 | 67.87 | 147 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +5.9% | -1.4% | +14.3% | -0.5% | +34.9% | +12.8% | - |
| EBITDA growth | +8.1% | +379.1% | -55.8% | +309.4% | -146.1% | +31.4% | - |
| PBT growth | +10.7% | +9998.0% | - | +9998.0% | - | +51.3% | +7.7% |
| Net income growth | -16.7% | +1660.6% | -116.2% | +152.3% | -287.8% | +194.2% | - |
| Revenue CAGR (3Y) | +6.1% | +3.9% | +15.4% | +14.8% | +30.5% | +23.0% | - |
| EBITDA CAGR (3Y) | +31.8% | - | -24.7% | +8.2% | - | +22.4% | - |
| Profitability & leverage | |||||||
| Net income margin | +5.9% | +8.4% | +0.0% | +2.7% | -6.8% | +4.5% | +1.8% |
| Return on capital employed | +12.5% | +12.9% | +1.2% | +11.7% | -9.4% | +11.6% | +9.3% |
| Return on net worth | +8.1% | +18.3% | -2.2% | +19.5% | -33.3% | +15.4% | +6.0% |
| Debt / equity | 0.04 | 0.17 | 0.83 | 0.76 | 0.33 | 0.19 | 0.24 |
| Long-term debt / equity | 0.02 | 0.06 | 0.24 | 0.18 | 0.03 | 0.02 | 0.01 |
| Interest cover | 27.07 | 11.12 | -176.40 | 43.44 | -8.36 | 4.28 | 18.75 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.87 | 2.00 | 2.34 | 2.28 | 2.66 | 2.35 | 2.43 |
| Inventory turnover | 6.07 | 6.28 | 6.14 | 5.03 | 6.37 | 6.57 | 6.06 |
| Debtors turnover | 5.56 | 5.13 | 4.98 | 4.23 | 5.19 | 4.89 | 4.15 |
| EPS (₹) | 16.67 | 22.09 | (0.28) | 6.63 | (35.30) | 943.16 | 335.65 |
| Dividend per share (₹) | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 216.41 | 199.01 | 49.59 | 50.13 | 86.95 | 6,801.28 | 5,554.41 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 395 | 392 | 338 | 369 | 309 | 332 | 329 | 337 |
| Revenue growth (YoY) | +27.7% | +18.0% | +2.9% | +9.3% | -5.8% | +4.8% | - | - |
| Other income | 25.80 | 26.10 | 27.73 | 29.60 | 27.08 | 28.56 | 32.05 | 33.84 |
| Total expenses | 360 | 344 | 329 | 348 | 292 | 288 | 311 | 303 |
| EBITDA | 34.57 | 48.51 | 9.07 | 20.87 | 16.90 | 44.10 | 17.72 | 34.03 |
| EBITDA margin | +8.8% | +12.4% | +2.7% | +5.7% | +5.5% | +13.3% | +5.4% | +10.1% |
| Depreciation | 13.51 | 12.80 | 12.42 | 12.15 | 10.69 | 10.25 | 10.09 | 10.68 |
| Interest | 3.00 | 2.48 | 2.59 | 2.46 | 2.08 | 2.91 | 2.63 | 2.29 |
| Profit before tax | 43.86 | 59.33 | 21.79 | 35.86 | 31.21 | 59.50 | 37.05 | 54.90 |
| Tax | 11.21 | 14.50 | 6.60 | 7.75 | 7.74 | 14.64 | 9.47 | 13.73 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,349 | 1,312 | 1,444 | 1,287 | 1,162 | 837 | 737 |
| Revenue growth | +2.8% | -9.2% | +12.2% | +10.7% | +38.8% | +13.6% | - |
| Other income | 113 | 124 | 94.12 | 96.15 | 58.48 | 54.51 | 65.52 |
| Total expenses | 1,258 | 1,173 | 1,590 | 1,189 | 1,524 | 1,060 | 697 |
| Employee cost | 218 | 202 | 175 | 147 | 136 | 123 | 124 |
| EBITDA | 90.96 | 138 | (146) | 97.34 | (362) | (223) | 39.93 |
| EBITDA margin | +6.7% | +10.6% | -10.1% | +7.6% | -31.2% | -26.6% | +5.4% |
| Depreciation | 45.50 | 39.55 | 32.69 | 30.00 | 27.76 | 26.10 | 25.26 |
| Interest | 10.04 | 15.31 | 18.31 | 13.18 | 3.65 | 0.82 | 4.34 |
| Profit before tax | 148 | 208 | (103) | 150 | (335) | (195) | 75.85 |
| Tax | 36.72 | 46.83 | 62.52 | 24.89 | 46.80 | (49.77) | 24.99 |
| Net profit | 117 | 158 | (157) | 231 | (383) | 110 | 50.84 |
| Net profit margin | +8.6% | +12.1% | -10.9% | +17.9% | -32.9% | +13.2% | +6.9% |
| EPS (₹) | 7.29 | 10.52 | (11.56) | 8.77 | (53.37) | (1,117.82) | 391.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 30.62 | 30.62 | 28.61 | 28.61 | 14.31 | 1.30 | 1.30 |
| Reserves & surplus | 2,397 | 2,275 | 115 | 283 | 171 | 566 | 711 |
| Shareholders' funds (net worth) | 2,428 | 2,305 | 144 | 312 | 186 | 567 | 712 |
| Secured loans | 13.55 | 3.93 | 226 | 146 | 122 | 22.71 | 35.80 |
| Unsecured loans | 45.66 | 42.36 | 40.78 | 0.00 | 18.07 | 18.42 | 0.00 |
| Total debt | 59.21 | 46.29 | 267 | 146 | 140 | 41.13 | 35.80 |
| Total liabilities | 2,516 | 2,374 | 1,796 | 1,521 | 1,389 | 1,176 | 1,262 |
| Assets | |||||||
| Gross block | 792 | 683 | 613 | 532 | 497 | 463 | 436 |
| Net block | 425 | 356 | 317 | 272 | 253 | 244 | 242 |
| Capital work in progress | 52.23 | 56.74 | 8.65 | 16.25 | 0.52 | 1.26 | 1.13 |
| Investments | 366 | 366 | 139 | 139 | 141 | 149 | 65.35 |
| Inventories | 230 | 202 | 162 | 197 | 179 | 95.91 | 123 |
| Sundry debtors | 218 | 206 | 234 | 256 | 304 | 212 | 178 |
| Cash & bank balances | 771 | 356 | 73.31 | 8.85 | 25.74 | 1.00 | 72.48 |
| Loans & advances | 105 | 69.24 | 64.43 | 58.99 | 46.19 | 43.02 | 121 |
| Total current assets | 1,324 | 833 | 533 | 521 | 555 | 352 | 494 |
| Total current liabilities | 289 | 303 | 289 | 373 | 412 | 122 | 142 |
| Net working capital | 1,035 | 530 | 244 | 148 | 143 | 230 | 352 |
| Total assets | 2,516 | 2,374 | 1,796 | 1,521 | 1,389 | 1,176 | 1,262 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 76.49 | 68.96 | 7.23 | 25.49 | 0.15 | 41.93 | 3.87 |
| Net cash from operating activities | (2.15) | 91.00 | 248 | 94.01 | 228 | 55.57 | (21.75) |
| Net cash from investing activities | (24.97) | (459) | (165) | (202) | (298) | (99.96) | (242) |
| Net cash from financing activities | (3.00) | 375 | (20.74) | 89.90 | 94.99 | 2.60 | 302 |
| Net change in cash | (30.11) | 7.54 | 61.72 | (18.26) | 25.34 | (41.79) | 38.07 |
| Closing cash | 771 | 356 | 73.31 | 8.85 | 25.74 | 1.00 | 72.48 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +2.8% | -9.2% | +12.2% | +10.7% | +38.8% | +13.6% | - |
| EBITDA growth | -34.3% | +194.8% | -250.0% | +126.9% | -62.5% | -658.0% | - |
| PBT growth | -28.6% | +9998.0% | - | +9998.0% | -71.6% | - | -32.3% |
| Net income growth | -26.4% | +200.6% | -168.3% | +160.2% | -447.0% | +117.0% | - |
| Revenue CAGR (3Y) | +1.6% | +4.1% | +19.9% | +20.4% | +19.4% | +12.0% | - |
| EBITDA CAGR (3Y) | -2.2% | - | -13.1% | +34.6% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +8.3% | +12.3% | -11.5% | +9.8% | -32.9% | -17.4% | +6.9% |
| Return on capital employed | +6.5% | +10.7% | -3.9% | +21.2% | -25.8% | +4.5% | +7.4% |
| Return on net worth | +4.7% | +13.2% | -69.2% | +92.8% | -101.5% | +17.3% | +6.6% |
| Debt / equity | 0.02 | 0.13 | 0.91 | 0.57 | 0.22 | 0.05 | 0.06 |
| Long-term debt / equity | 0.02 | 0.04 | 0.17 | 0.08 | -30,181.49 | -17,754.29 | 0.00 |
| Interest cover | 22.09 | 15.47 | -10.24 | 19.57 | -0.94 | -0.33 | 29.58 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.83 | 2.02 | 2.52 | 2.50 | 2.42 | 1.86 | 1.79 |
| Inventory turnover | 6.25 | 7.22 | 8.05 | 6.84 | 8.44 | 7.65 | 6.43 |
| Debtors turnover | 6.37 | 5.96 | 5.90 | 4.60 | 4.51 | 4.30 | 4.38 |
| EPS (₹) | 7.29 | 10.52 | (11.56) | 8.77 | (53.37) | (1,117.82) | 391.04 |
| Dividend per share (₹) | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 158.56 | 150.57 | 10.06 | 21.77 | 25.94 | 4,358.55 | 5,476.91 |
To see the full year-wise statements and ratios of Akums Drugs and Pharmaceuticals Limited, buy the company report.
Board of directors of Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals has 8 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kewal Kundanlal Handa Also directs: The Third Eye Kreative Films LLP, The Third Eye Productions LLP, Titiksha Advisors LLP and 5 more | Director | 16 Mar 2022 | 4 Years 8 Months | Current |
| Matangi Gowrishankar Also directs: Greenlam Industries Limited, Cohance Lifesciences Limited, Dhoot Transmission Limited and 5 more | Director | 16 Mar 2022 | 4 Years 8 Months | Current |
| Sandeep Jain | Managing Director | 19 Apr 2004 | 22 Years 7 Months | Current |
| Sanjeev Jain | Managing Director | 19 Apr 2004 | 22 Years 7 Months | Current |
| Anilkumar Arvindlal Amin Also directs: Black Gold Recycling Private Limited | Director | 04 Jun 2025 | 1 Years 5 Months | Current |
| Satwinder Singh | Director | 17 Jan 2024 | 2 Years 10 Months | Current |
Peer comparison
Akums Drugs and Pharmaceuticals Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Strides Pharma Science Limited | ₹4,624.06 Cr (FY 2025) | 18.0% | Thane, Maharashtra, India | |||
| Apl Healthcare Limited | ₹4,412.92 Cr (FY 2025) | 39.0% | Hyderabad, Telangana, India | |||
| Akums Drugs and Pharmaceuticals Limitedthis company | ₹4,359.02 Cr (FY 2026) | ₹268.66 Cr | 6.2% | 5.8% | 1,707 | Delhi, India |
| J B Chemicals and Pharmaceuticals Limited | ₹3,956.31 Cr (FY 2025) | 12.0% | Ahmedabad, Gujarat, India | |||
| Glaxosmithkline Pharmaceuticals Limited | ₹3,895.14 Cr (FY 2025) | 9.0% | Mumbai, Maharashtra, India | |||
| Cadila Pharmaceuticals Limited | ₹3,869.17 Cr (FY 2025) | 4.0% | Ahmedabad, Gujarat, India |
To see the full peer comparison of Akums Drugs and Pharmaceuticals Limited, buy the company report.
Auditor
Akums Drugs and Pharmaceuticals Limited is audited by M/S Walker Chandiok & Llp for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| M/S Walker Chandiok & Llp | FY 2025 | 001076N/N500013 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 75.30%, foreign institutional investors hold 1.90%, domestic institutional investors hold 13.50% and retail and other public shareholders hold 9.30%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 75.30% | 75.30% | 75.30% | 75.30% |
| Public | 24.70% | 24.70% | 24.70% | 24.70% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 08 Feb 2023 | 100679965 | Sbicap Trustee Company Limited | ₹85 Cr | Open | |
| 15 Jul 2022 | 100598017 | Yes Bank Limited | ₹60 Cr | Satisfied | |
| 13 Jul 2022 | 100601001 | The Hongkong and Shanghai Banking Corporation Limited | ₹50 Cr | Satisfied | |
| 11 Apr 2022 | 100565416 | Citi Bank N.A. | ₹25 Cr | Satisfied | |
| 16 Aug 2021 | 100494543 | Hdfc Bank Limited | ₹60 Cr | Satisfied |
To see the full charge records of Akums Drugs and Pharmaceuticals Limited, buy the company report.
Total charge records: 18 View all charges
Deals & funding
Akums Drugs and Pharmaceuticals Limited has 13 deals on record (9 secondary share transfers, 2 market trades, 1 ipo), with disclosed funding of ₹320 Cr; the latest was in December 2025.
Deals on record (5 of 13)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2025 | Market trade | ₹311.52 Cr | Buyer: Icici Prudential Mutual Fund Seller: Ruby Qc Investment Holdings Pte.Ltd. |
| Aug 2024 | IPO | ₹1,856.74 Cr | Investors: IPO Shareholders - Akums Drugs And Pharmaceuticals Limited, SBI Healthcare Opportunities Fund, International Growth and Income Fund Seller: Quadria Capital, 3 individuals |
| Jan 2009 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Akum Pharmaceuticals Private Limited |
| Nov 2007 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: A.K. Laboratories Limited |
| Aug 2006 | Secondary share transfer | Undisclosed | Buyer: Akum Pharmaceuticals Private Limited , 3 individuals Seller: 4 individuals |
To see the full deal history of Akums Drugs and Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Akums Drugs and Pharmaceuticals Limited has 206 court cases on record: 138 filed by Akums Drugs and Pharmaceuticals, 68 filed against it. 51 cases are pending and 155 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 103 | 22 | 29 |
| District courts | 87 | 32 | 21 |
| NCLAT | 9 | 9 | 1 |
| Supreme Court | 4 | 3 | 0 |
| NCLT | 3 | 2 | 0 |
Cases on record (5 of 206)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, West, Delhi | Commercial suit | Filed against the company by M/S Bakshi Mark Pvt Ltd | Pending |
| District court, New Delhi, Delhi | Cheque dishonour complaint | Filed by the company against Ms Apco Medicare India Private Limited and Ors | Pending |
| High Court | Court case (COMIP) | Filed against the company by Sun Pharmaceutical Industries Limited and 1 other | Pending |
| High Court of Delhi | Commercial suit | Filed by the company against Premedium Pharmaceuticals Pvt Ltd & Ors. | Pending |
| High Court, GUJARAT | Court case (RA) | Filed by the company against Troikaa Pharmaceuticals Ltd. and 2 others | Pending |
To see the full case history of Akums Drugs and Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Akums Drugs and Pharmaceuticals Limited was last rated by Icra on 09 Jun 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 09 Jun 2021 |
To see the full credit ratings and regulatory alerts of Akums Drugs and Pharmaceuticals Limited, buy the company report.
MSME payment delays
Akums Drugs and Pharmaceuticals Limited has 2 MSME Form 1 returns on record between 2019 and 2021, listing 8 overdue payments to 8 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 8)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Trident Services Private Limited | |||
| an individual supplier | |||
| Super Lifecare Private Limited | |||
| Gogia Chemical Industries Private Limited | |||
| Kumaon Exports Private Limited |
To see the full MSME payment records of Akums Drugs and Pharmaceuticals Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Akums Drugs and Pharmaceuticals has 14 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| May and Baker Pharmaceuticals Limited | U15400DL2006PLC145272 | |
| Pure and Cure Healthcare Private Limited | U24232DL2005PTC266385 | |
| Plenteous Pharmaceuticals Limited | U24232DL2008PLC185686 | |
| Nicholas Healthcare Limited | U24232DL2009PLC186841 | |
| Unosource Pharma Limited | U24233DL2013PLC262364 | |
| Burroughs Welcome Pharmacia Private Limited | U24290DL2021PTC376044 |
To see the full group structure of Akums Drugs and Pharmaceuticals Limited, buy the company report.
Employees & EPFO
Akums Drugs and Pharmaceuticals Limited has a workforce of 1,707 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 1,707 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Akums Drugs and Pharmaceuticals Limited, buy the company report.
GST
Akums Drugs and Pharmaceuticals has 9 GST registrations: 5 active and 4 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAECA7090B2ZX | Delhi | Active | 26 Jul 2017 |
| 07AAECA7090B4ZV | Delhi | Active | 01 Mar 2025 |
| 05AAECA7090B1Z2 | Uttarakhand | Active | 01 Jul 2017 |
| 27AAECA7090B1ZW | Maharashtra | Active | 01 Aug 2019 |
To see the full GST registrations and return filing status of Akums Drugs and Pharmaceuticals Limited, buy the company report.
Recent activity
Akums Drugs and Pharmaceuticals Limited has 44 board changes on record since 2004: 27 appointments and 17 cessations. The latest: Anilkumar Arvindlal Amin was appointed as Director on 04 Jun 2025.
78 earlier events are in the company report.
News
Frequently asked questions
Akums Drugs and Pharmaceuticals is an active public limited company based in Delhi, India. The company works in chemical products, within the chemicals industry. It was incorporated on 19 April 2004 (22+ years old) and is registered under CIN L24239DL2004PLC125888. Listed on BSE: 544222 and NSE: AKUMS.
Akums Drugs and Pharmaceuticals reported revenue of ₹4,359.02 Cr for FY 2025-26 (up 5.8% YoY) based on consolidated financials.
Akums Drugs and Pharmaceuticals has 8 current directors:
- Sandeep Jain - Managing Director
- Sanjeev Jain - Managing Director
- Sanjay Sinha - Whole-Time Director
- Kewal Kundanlal Handa - Director
- Matangi Gowrishankar - Director
- Anilkumar Arvindlal Amin - Director
- Satwinder Singh - Director
- Sunil Kumar Thakur - Nominee Director
The latest financial statements of Akums Drugs and Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 10 July 2026. Year-wise statements from 2015 are in the company report.
The GSTIN of Akums Drugs and Pharmaceuticals is 07AAECA7090B2ZX, registered in Delhi. The company has 9 GST registrations in all, of which 5 are active and 4 are cancelled or inactive. Other active GSTINs include 07AAECA7090B4ZV (Delhi), 05AAECA7090B1Z2 (Uttarakhand), 27AAECA7090B1ZW (Maharashtra).
The CIN (Corporate Identification Number) of Akums Drugs and Pharmaceuticals is L24239DL2004PLC125888. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Akums Drugs and Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 544222) and NSE (symbol: AKUMS).
Akums Drugs and Pharmaceuticals has 206 court cases on record: 138 filed by the company and 68 filed against it. 51 are pending. Most are in the high courts.
Akums Drugs and Pharmaceuticals was incorporated on 19 April 2004, making it 22+ years old. It is registered with the Registrar of Companies, Delhi.
Akums Drugs and Pharmaceuticals has 13 deals on record (9 secondary share transfers, 2 market trades, 1 ipo), with disclosed funding of ₹320 Cr; the latest was in December 2025.
The peers of Akums Drugs and Pharmaceuticals by revenue are Strides Pharma Science Limited, Apl Healthcare Limited, J B Chemicals and Pharmaceuticals Limited, Glaxosmithkline Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).
Anilkumar Arvindlal Amin was appointed as Director on 04 Jun 2025. Nand Lal Kalra ceased to be Director on 05 Feb 2025. Amit Varma ceased to be Director on 17 Jan 2024. Akums Drugs and Pharmaceuticals has 44 board changes on record in total.

